COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)

被引：0
|
作者：
Woods, B. [1 ]
Thompson, J. [1 ]
Barcena, L. [1 ]
Liu, Y. [2 ]
Huang, H. [2 ]
Martinez, C. [3 ]
机构：
[1] Oxford Outcomes, Oxford, England
[2] Millennium Pharmaceut Inc, Cambridge, MA USA
[3] Inst Hematol & Oncol, Barcelona, Spain
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1728
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A509 / A509
页数：1
相关论文
共 50 条
  • [41] Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma
    Sasse, Stephanie
    Rothe, Achim
    Goergen, Helen
    Eichenauer, Dennis A.
    Lohri, Andreas
    Kreher, Stephan
    Jaeger, Ulrich
    Bangard, Christopher
    Kuhnert, Georg
    Boell, Boris
    von Tresckow, Bastian
    Engert, Andreas
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2144 - 2148
  • [42] Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma
    Moussab Damlaj
    Khadega A. Abuelgasim
    Ayman Alhejazi
    Bader Alahmari
    Ahmed Alaskar
    Mohsen Alzahrani
    Bone Marrow Transplantation, 2020, 55 : 2322 - 2325
  • [43] POST TRANSPLANT OUTCOMES IN A MULTICENTER PHASE II STUDY OF BRENTUXIMAB VEDOTIN AS FIRST LINE SALVAGE THERAPY IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
    Herrera, A.
    Palmer, J.
    Martin, P.
    Armenian, S.
    Tsai, N. -C.
    Mott, M.
    Sahebi, F.
    Cai, J. -L.
    Siddiqi, T.
    Popplewell, L.
    Nademanee, A.
    Rosen, S.
    Kwak, L.
    Forman, S.
    Chen, R.
    HAEMATOLOGICA, 2016, 101 : 47 - 48
  • [44] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Ishizawa, Kenichi
    Yanai, Tomoko
    ADVANCES IN THERAPY, 2019, 36 (10) : 2679 - 2696
  • [45] Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    Kenichi Ishizawa
    Tomoko Yanai
    Advances in Therapy, 2019, 36 : 2679 - 2696
  • [46] Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy
    Walewski, Jan
    Hellmann, Andrzej
    Siritanaratkul, Noppadol
    Ozsan, Guner Hayri
    Ozcan, Muhit
    Chuncharunee, Suporn
    Goh, Ai Sim
    Jurczak, Wojciech
    Koren, Jan
    Paszkiewicz-Kozik, Ewa
    Wang, Bingxia
    Singh, Shalini
    Huebner, Dirk
    Engert, Andreas
    von Tresckow, Bastian
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (03) : 400 - 410
  • [47] A targeted salvage therapy with brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients who received autologuos stem cell transplantation (ASCT).
    Tacyildiz, Nurdan
    Unal, Emel
    Yavuz, Gulsan
    Dincaslan, Handan
    Tanyildiz, Gulsah
    Pekpak, Esra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients
    Flerlage, Jamie E.
    von Buttlar, Xinyu
    Krasin, Matthew
    Triplett, Brandon
    Kaste, Sue C.
    Metzger, Monika L.
    PEDIATRIC BLOOD & CANCER, 2019, 66 (12)
  • [49] Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
    Chen, Robert
    Gopal, Ajay K.
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Connors, Joseph M.
    Engert, Andreas
    Larsen, Emily K.
    Huebner, Dirk
    Fong, Abraham
    Younes, Anas
    BLOOD, 2016, 128 (12) : 1562 - 1566
  • [50] Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse
    Sweetenham, John W.
    Walewski, Jan
    Nadamanee, Auayporn
    Masszi, Tamas
    Agura, Edward
    Holowiecki, Jerzy
    Abidi, Muneer H.
    Chen, Andy L.
    Stiff, Pat
    Viviani, Simonetta
    Carella, Angelo
    Osmanov, Dzhelil
    Bachanova, Veronika
    Sureda, Anna
    Huebner, Dirk
    Larsen, Emily K.
    Hunder, Naomi N.
    Moskowitz, Craig H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S36 - S37
12345